FLT3 and acute myeloid leukemia: The cytotoxicity of the MEN1703–gilteritinib combination was also explored in AML primary samples obtained from gilteritinib‐naïve and gilteritinib‐treated patients harbouring FLT3‐ITD and other AML‐relevant mutations (Table S1).